<- Go Home

Instem Limited

Instem Limited, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Blur Clinical Annonymization; Logbook ELN, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a windows-based system for non-clinical evaluation studies. In addition, it provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; KnowledgeScan Target Safety Assessment services; SENDTrial, a web based solution that can be accessed through a subscription; and Predict delivers computational models. Further, the company provides Sorcerer Colony Counter; sales and administrative support; training, validation, consultancy, cloud, and safety assessment and regulatory information management software services; software solutions to extract intelligence from research and development related healthcare data; and holds intellectual property rights and investment. It also develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem Limitedwas formerly known as Instem plc and changed its name to Instem Limited in December 2023. Instem Limited was founded in 1969 and is headquartered in Stone, the United Kingdom. As of November 20, 2023, Instem Limited was taken private.

Market Cap

N/A

Volume

91.1K

Cash and Equivalents

GBP 11.7M

EBITDA

GBP 5.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

GBP 24.1M

Profit Margin

39.92%

52 Week High

N/A

52 Week Low

N/A

Dividend

N/A

Price / Book Value

N/A

Price / Earnings

N/A

Price / Tangible Book Value

N/A

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

GBP 3.6M

Return on Equity

12.72%

Return on Assets

2.47

Cash and Short Term Investments

GBP 11.7M

Debt

GBP 6.4M

Equity

GBP 48.0M

Revenue

GBP 60.4M

Unlevered FCF

GBP 2.8M

Sector

Health Care Technology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches